Publications

Publications

Filter Results: (1,245) Arrow Down
Filter Results: (1,245) Arrow Down Arrow Up

Show Results For

Show Results For

← Page 23 of 1,245 Results →

    Srikant M. Datar

    Srikant M. Datar became the eleventh dean of Harvard Business School on 1 January 2021. During his tenure as a faculty member, he served as Senior Associate Dean for University Affairs (including Faculty Chair of the Harvard Innovation Lab), for Research, for... View Details

    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
    • January 2009
    • Case

    When Supply is of Public Interest: Roche & Tamiflu

    The case focuses on the challenges of Roche maintaining a supply network for a global influenza pandemic response initiative based on its antiviral drug Tamiflu. The Roche group is a 40 billion CHF company consisting of a pharmaceutical division and a diagnostic... View Details
    Keywords: Global Strategy; Health Pandemics; Distribution; Logistics; Production; Supply Chain Management; Performance Capacity; Pharmaceutical Industry
    Related
    • 2025
    • Working Paper

    Combining Complements: Theory and Evidence from Cancer Treatment Innovation

    By: Rebekah Dix and Todd A. Lensman
    Innovations often combine several components to achieve outcomes greater than the “sum of the parts.” We argue that such combination innovations can introduce an understudied inefficiency—a positive market expansion externality that benefits the owners of the... View Details
    Keywords: Innovation Strategy; Outcome or Result; Collaborative Innovation and Invention; Health Testing and Trials; Health Industry
    Related
    • July 2023
    • Case

    HealthVerity: Real World Data and Evidence

    By: Satish Tadikonda
    Andrew Kress (CEO and founder) and his team had built a promising marketplace business at HealthVerity serving its core market in healthcare, with a focus on pharmaceutical R&D and services. Thus far, HealthVerity’s products had been unique to the pharma and pharma... View Details
    Keywords: Growth and Development Strategy; Market Entry and Exit; Product Marketing
    Related
    • December 2018
    • Case

    Corporate Transformation at Merck KGaA, Darmstadt, Germany

    By: Joseph B. Fuller, Amy C. Edmondson, Daniela Beyersdorfer and Tonia Labruyere
    When Stefan Oschmann became CEO and chairman of the executive board of Merck KGaA, Darmstadt, Germany, in 2016, the company had started its transformation from a mid-tier traditional German industry player to a global modern science and technology player. The... View Details
    Keywords: Corporate Governance With Family Ownership; Transformation; Change Management; Restructuring; Corporate Governance; Family Ownership
    Related

      Ranjay Gulati

      Ranjay Gulati is the Paul R. Lawrence MBA Class of 1942 Professor of Business Administration and the former Unit Head of the Organizational Behavior Unit at Harvard Business School. His pathbreaking research, which focuses on unlocking organizational and unleashing... View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
      • Program

      Strategy for Health Care Delivery—Virtual

      for health care, or other payor organizations Leaders from pharmaceutical companies, medical device companies, or other health care supply companies—including startups and established firms Leaders in Virtual Learning This program... View Details
      Keywords: Health Care; Health Care
      • 16 May 2023
      • HBS Case

      How KKR Got More by Giving Ownership to the Factory Floor: ‘My Kids Are Going to College!’

      pharmaceuticals and technology. Rouen cautions that the model works best in fast-growing companies, where employees can receive a sizeable payout, and in situations where a sale in the not-too-distant future can translate into wealth.... View Details
      Keywords: by Avery Forman

        Paul A. Gompers

        Paul Gompers, Professor of Business Administration at the Harvard Business School, specializes in research on financial issues related to start-up, high growth, and newly public companies. Professor Gompers has an appointment in both the View Details
        Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
        • 02 Aug 2011
        • First Look

        First Look: August 2

        pharmaceutical and skin care company. During World War I the expropriation of its brands and trademarks revealed its vulnerability to political risk. Following the advent of the Nazi regime in 1933, the largely Jewish owned and managed... View Details
        Keywords: Sean Silverthorne

          Joshua D. Margolis

          Joshua Margolis is James Dinan and Elizabeth Miller Professor of Business Administration and the Unit Head for the Organizational Behavior unit. He is also Faculty Chair of the Program for Leadership Development. His research and teaching revolve around leadership... View Details

          Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
          • 31 Jan 2007
          • Working Paper Summaries

          Behavioral Decision Research, Legislation, and Society: Three Cases

          Keywords: by Max H. Bazerman

            Malcolm P. Baker

            Malcolm Baker is the Robert G. Kirby Professor of Business Administration at the Harvard Business School, where he teaches the required course in finance and a short immersive program on investing in life sciences.

            His research is in the... View Details

            Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
            • 28 Mar 2023
            • Research & Ideas

            The FDA’s Speedy Drug Approvals Are Safe: A Win-Win for Patients and Pharma Innovation

            Wiener Professor of Public Policy and Director of Health Policy Research at the Harvard Kennedy School of Government. Jennifer Kao of the University of California, Los Angeles and the FDA’s Kathleen Miller are also coauthors. Speeding innovation without compromising... View Details
            Keywords: by Kasandra Brabaw; Pharmaceutical

              Robert S. Huckman

              Robert Huckman is the Albert J. Weatherhead III Professor of Business Administration at Harvard Business School, the Howard Cox Faculty Chair of the HBS Healthcare Initiative, and the Senior Associate Dean for External... View Details

              Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

                V. Kasturi Rangan

                Kash Rangan is the Malcolm P. McNair Professor of Marketing at the Harvard Business School. Formerly the chairman of the Marketing Department (1998-2002), he is now the co-chairman of the school's Social Enterprise Initiative. He has taught in a wide variety of MBA... View Details

                Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
                • 21 Feb 2018
                • Research & Ideas

                When a Competitor Abandons the Market, Should You Advance or Retreat?

                Terminations: Learning from Competitors’ R&D Failures, Krieger explores how pharmaceutical companies choose to react strategically when a competitor exits the market during the development stage. These companies may decide further... View Details
                Keywords: by Rachel Layne; Pharmaceutical; Pharmaceutical

                  Krishna G. Palepu

                  KRISHNA G. PALEPU is the Ross Graham Walker Professor of Business Administration, and has served previously as Senior Advisor to the President of Harvard University, and Senior Associate Dean at the... View Details

                  Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

                    Rohit Deshpande

                    Rohit Deshpandé is a Baker Foundation Professor and Sebastian S. Kresge Professor of Marketing, Emeritus at Harvard Business School, where he has been teaching in the Advanced Management Program,... View Details

                    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
                    • 09 Feb 2024
                    • HBS Case

                    Slim Chance: Drugs Will Reshape the Weight Loss Industry, But Habit Change Might Be Elusive

                    Year after year, millions of people make a new year’s resolution to lose weight. But because success traditionally depends on making major lifestyle changes, like eating healthier and exercising more, many people fall short of their fitness goals. Yet in 2024, more... View Details
                    Keywords: by Lane Lambert; Pharmaceutical; Pharmaceutical